AstraZeneca Says Enhertu Approved in US as First-Line HER2 Positive Metastatic Breast Cancer Treatment
MT Newswires Live
Dec 16
AstraZeneca (AZN) said Monday that Enhertu, in combination with pertuzumab, has been approved in the US as a first-line treatment for adult patients with unresectable or metastatic HER2 positive breast cancer.
The approval has been based on Destiny-Breast09 phase 3 study results that showed Enhertu in combination with pertuzumab reduced the risk of disease progression by 44% versus taxane, trastuzumab and pertuzumab, AstraZeneca said.
Enhertu is an antibody drug conjugate discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, the company said.
Shares of AstraZeneca were up nearly 2% in recent Monday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.